Insight
Who Owns What Happens After the Test? The Accountability Gap in Longevity Programs
The Medical Layer Investors Skip When Funding Longevity and Performance Programs
Why Most Longevity Interventions Don't Survive Past Week 6
Evidence on the Ingredient vs. Evidence on the Product: What Longevity Investors Must Ask
Why "GLP-1 Customer" Is Not a Single Segment for Longevity Businesses
Build, Convert, or Ring Fence: The First Decision in a Hospital Longevity Clinic
Building a Longevity Business That Pays for Itself: The Multi-Customer Model
The Hidden Economics of Athlete Longevity: What Sports Clubs Are Missing
Why Diagnostics Alone Don't Make a Longevity Business
